These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 2483885)

  • 21. Prevention of HIV-2 and SIVSM infection in cynomolgus monkeys by active or passive immunization.
    Biberfield G; Putkonen P; Thorstensson R; Norrby E
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1511-3. PubMed ID: 1466992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T- and B-cell functions and epitope expression in nonhuman primates immunized with simian immunodeficiency virus antigen by the rectal route.
    Lehner T; Brookes R; Panagiotidi C; Tao L; Klavinskis LS; Walker J; Walker P; Ward R; Hussain L; Gearing JH
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8638-42. PubMed ID: 7690967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are we detouring from a direct route to development of HIV vaccines?
    Fultz PN
    Vaccine; 1991 Nov; 9(11):783-7. PubMed ID: 1759499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural constraints on viral escape from HIV- and SIV-specific cytotoxic T-lymphocytes.
    Peyerl FW; Barouch DH; Letvin NL
    Viral Immunol; 2004; 17(2):144-51. PubMed ID: 15279695
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV.
    Hu X; Valentin A; Dayton F; Kulkarni V; Alicea C; Rosati M; Chowdhury B; Gautam R; Broderick KE; Sardesai NY; Martin MA; Mullins JI; Pavlakis GN; Felber BK
    J Immunol; 2016 Nov; 197(10):3999-4013. PubMed ID: 27733554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New multiple antigenic peptide-based enzyme immunoassay for detection of simian immunodeficiency virus infection in nonhuman primates and humans.
    Ndongmo CB; Switzer WM; Pau CP; Zeh C; Schaefer A; Pieniazek D; Folks TM; Kalish ML
    J Clin Microbiol; 2004 Nov; 42(11):5161-9. PubMed ID: 15528710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection.
    Munson P; Liu Y; Bratt D; Fuller JT; Hu X; Pavlakis GN; Felber BK; Mullins JI; Fuller DH
    Hum Vaccin Immunother; 2018 Jul; 14(7):1820-1831. PubMed ID: 29648490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies.
    Warren JT; Dolatshahi M
    J Med Primatol; 1993; 22(2-3):203-35. PubMed ID: 8411110
    [No Abstract]   [Full Text] [Related]  

  • 31. Roundtable: can experience with veterinary retroviral vaccines be applied to the human situation?
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):365-73. PubMed ID: 8882312
    [No Abstract]   [Full Text] [Related]  

  • 32. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.
    Xu W; Hofmann-Lehmann R; McClure HM; Ruprecht RM
    Vaccine; 2002 May; 20(15):1956-60. PubMed ID: 11983253
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonhuman primates and the acquired immunodeficiency syndrome: a union of necessity.
    Fultz PN
    J Med Primatol; 1989; 18(2):73-83. PubMed ID: 2541246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
    Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
    J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AIDS vaccine study reported.
    Am Fam Physician; 1990 Feb; 41(2):684, 686. PubMed ID: 2154084
    [No Abstract]   [Full Text] [Related]  

  • 36. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.
    Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaün JJ; Gallo RC; Shearer GM; Zagury D
    Nature; 1988 Aug; 334(6184):706-8. PubMed ID: 2457809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective mucosal immunity elicited by targeted lymph node immunization with a subunit SIV envelope and core vaccine in macaques.
    Lehner T; Wang Y; Cranage M; Bergmeier LA; Mitchell E; Tao L; Hall G; Dennis M; Cook N; Jones I; Doyle C
    Dev Biol Stand; 1998; 92():225-35. PubMed ID: 9554279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approaches to preventative and therapeutic HIV vaccines.
    Gray GE; Laher F; Lazarus E; Ensoli B; Corey L
    Curr Opin Virol; 2016 Apr; 17():104-109. PubMed ID: 26985884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques.
    Ourmanov I; Bilska M; Hirsch VM; Montefiori DC
    J Virol; 2000 Mar; 74(6):2960-5. PubMed ID: 10684319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.